Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Summary

Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end of trial. The end of trial is one year after the last patient has entered the study.

Timeline

Start

2015-08-18

Primary completion

2019-03-28

Completion

2019-04-25

Drugs

Indications